GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: ALD-1910 | ALD1910 | LU AG-09222 | Lu AG09222 | Lu-AG09222 | LuAG09222
Compound class:
Antibody
Comment: Bocunebart (Lu AG09222 from Lundbeck; formerly ALD1910) is a humanized monoclonal antibody that targets both isoforms of PACAP (PACAP-27 and PACAP-38) [1-2]. It is designed to disrupt PACAP signaling via its receptors as a mechanism to reduce migraine episodes [2-3]. The PACAP epitope engaged by Lu AG09222 is nonlinear, with interactions at amino acids in positions 19, 22, 23, and/or 27 required for potent binding.
|
| No information available. |
Summary of Clinical Use ![]() |
| Lu AG09222 was progressed to clinical evaluation to determine safety and efficacy as an anti-migraine therapy. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT04976309 | A Single Dose Study of Lu AG09222 in a Headache Model With Healthy Subjects | Phase 1 Interventional | H. Lundbeck A/S | 3 | |
| NCT05133323 | A Study With Lu AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments | Phase 2 Interventional | H. Lundbeck A/S | ||
| NCT06323928 | A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments | Phase 2 Interventional | H. Lundbeck A/S | ||
| NCT04197349 | Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman | Phase 1 Interventional | H. Lundbeck A/S | ||